Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial

Results provide preliminary evidence supporting efficacy and tolerability of a full-spectrum, high-CBD product for anxiety. Patients quickly achieve and maintain symptom reduction with few side effects. A definitive assessment of the impact of this novel treatment on clinical symptoms and cognition will be ascertained in the ongoing double-blind, placebo-controlled stage.

Share with someone who may find this helpful

You are welcome to send this page to a friend, family member or anyone who may be interested. There is no need to explain why, or to share anything about yourself.

The message includes the page title, and you can change it before sending. This website only counts that a share button was used; it never sees who you send it to.